Buprenorphine is a semi-synthetic opioid analgesic derived from thebaine. At the 0.3mg strength, it is primarily indicated for the management of moderate to severe acute pain. It is a partial mu-opioid receptor agonist and a kappa-opioid receptor antagonist, offering a unique pharmacological profile with a ceiling effect on respiratory depression, making it potentially safer than full agonists in certain contexts. In India, it is a critical component of pain management protocols and is also used in opioid dependence treatment at higher doses.
Adult: For Pain (Sublingual/IM): 0.3mg every 6-8 hours as needed for pain. Dose may be repeated once in 30-60 minutes if needed. Usual range: 0.3mg - 0.6mg per dose. For Opioid Dependence: Not applicable at this low strength; higher fixed-dose combinations (e.g., with naloxone) are used.
Note: Sublingual Tablet: Place under the tongue until completely dissolved (5-10 minutes). Do not chew, swallow, or talk while tablet dissolves. Avoid eating or drinking for 15 minutes after administration. Intramuscular Injection: Administer deep IM into a large muscle mass. Rotate injection sites.
Buprenorphine binds with high affinity to central nervous system mu-opioid receptors (MOR) and kappa-opioid receptors (KOR). At the MOR, it acts as a partial agonist, producing analgesic and subjective effects but with a ceiling (plateau) effect. At the KOR, it acts as an antagonist, which may contribute to a lower incidence of dysphoria and psychotomimetic effects compared to some other opioids.
Pregnancy: Pregnancy Category C (US FDA). May cause fetal harm. Use only if potential benefit justifies potential risk to the fetus. Chronic use during pregnancy can result in Neonatal Opioid Withdrawal Syndrome (NOWS), which may be life-threatening. NOT recommended for analgesia during labor (can cause neonatal respiratory depression).
Driving: May impair mental and/or physical abilities required for driving or operating machinery. Patients should be cautioned not to drive or use machinery until they know how the medication affects them, especially during initiation and dose titration.
| Benzodiazepines (e.g., Alprazolam, Diazepam) | Profound sedation, respiratory depression, coma, and death. | Major |
| Other CNS Depressants (Alcohol, Barbiturates, Sedative-hypnotics) | Additive CNS and respiratory depression. | Major |
| Other Opioid Agonists (Morphine, Fentanyl, Codeine) | Buprenorphine may block effects or precipitate withdrawal due to its high receptor affinity. | Major |
| CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin, Ritonavir) | Increased buprenorphine plasma levels, risk of toxicity. | Moderate |
| CYP3A4 Inducers (Rifampicin, Carbamazepine, Phenytoin, St. John's Wort) | Decreased buprenorphine plasma levels, reduced efficacy, potential withdrawal. | Moderate |
| Serotonergic Drugs (SSRIs, SNRIs, TCAs, Tramadol) | Increased risk of serotonin syndrome. | Moderate |
| Anticholinergics | Increased risk of urinary retention and severe constipation. | Moderate |
| MAO Inhibitors | Potentially fatal serotonin syndrome or opioid toxicity; contraindicated. | Contraindicated |
Same composition (Buprenorphine (0.3mg)), different brands: